Browse the evidence

Once-weekly subcutaneous semaglutide 2.4 mg and tirzepatide 10-15 mg induce large, sustained reductions in body weight and waist circumference in adults with obesity without diabetes, significantly outperforming lifestyle interventions alone.

For individuals with obesity who have not achieved sustained weight loss through lifestyle changes alone, adding once-weekly semaglutide (2.4 mg) or tirzepatide (10-15 mg) to a lifestyle program can result in significant, clinically meaningful weight loss (12-19%) and waist circumference reduction. These treatments are generally well-tolerated, with side effects typically being mild gastrointestinal issues that diminish over time.

Tirzepatide (5-15 mg once weekly) produces superior weight loss (16-22.5% mean reduction) compared to placebo and other GLP-1 RAs by acting as a dual GLP-1 and GIP receptor agonist.

Tirzepatide is a once-weekly injection that significantly reduces body weight (16-22.5%) in adults with overweight or obesity. It works by mimicking two gut hormones (GLP-1 and GIP) to increase satiety and reduce food intake. Treatment starts at a low dose (2.5 mg) and increases every 4 weeks to minimize side effects like nausea. It is most effective when combined with lifestyle changes, including a caloric deficit and regular physical activity.

Once-weekly subcutaneous semaglutide 2.4 mg induces greater weight loss from baseline than placebo and once-daily liraglutide 3.0 mg in patients with overweight or obesity, with or without type 2 diabetes.

Semaglutide 2.4 mg is a once-weekly injection approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. It is taken alongside a calorie-controlled diet and increased physical activity. The dose starts low (0.25 mg) and increases every 4 weeks to 2.4 mg to minimize side effects. It is currently the most efficacious medication for weight loss, producing double-digit percentage body weight reductions over 1-2 years, superior to placebo and once-daily liraglutide.

Once-weekly subcutaneous semaglutide 2.4 mg, used as an adjunct to lifestyle intervention, significantly improves cardiometabolic risk factors—including waist circumference, HbA1c, blood pressure, and lipid profiles—in adults with overweight or obesity, with or without type 2 diabetes.

If you have obesity or overweight with related health risks, once-weekly semaglutide 2.4 mg, combined with a calorie-reduced diet and regular exercise, significantly improves key health markers like blood pressure, blood sugar, and cholesterol. This treatment is most effective when used long-term, as stopping it can reverse these benefits.

High-dose GLP-1 receptor agonists (semaglutide 2.4 mg and tirzepatide 15 mg) produce substantial, clinically significant weight loss in adults with obesity, with tirzepatide demonstrating superior efficacy compared to other agents.

If you have obesity, high-dose GLP-1 medications like semaglutide (2.4 mg weekly) or tirzepatide (15 mg weekly) are significantly more effective for weight loss than lifestyle changes alone. Tirzepatide showed the highest efficacy in this review. These treatments work by targeting hormonal pathways that regulate hunger and satiety, and they are most effective when combined with standard lifestyle counseling.

Tirzepatide administered once weekly produces significant weight loss (mean difference -16.32% body weight) and improves cardiometabolic markers (BMI, waist circumference, lipids, blood pressure) in patients with overweight or obesity without diabetes mellitus, though it carries a significantly elevated risk of gastrointestinal side effects.

For individuals with overweight or obesity without diabetes, tirzepatide is a highly effective pharmacological intervention for weight loss, producing greater reductions than GLP-1 RAs like semaglutide. It also improves blood pressure, lipids, and glycemic control. However, patients must be prepared for a high likelihood of gastrointestinal side effects (nausea, vomiting, diarrhea), which can lead to discontinuation. The overall risk of serious adverse events is not significantly higher than placebo, but the burden of GI symptoms is a key consideration for adherence.

GLP-1 receptor agonists significantly increase the likelihood of achieving weight loss compared to placebo, with tirzepatide and semaglutide demonstrating the highest relative efficacy among evaluated agents.

If you have obesity or overweight with related health issues, GLP-1 receptor agonists like semaglutide or tirzepatide are highly effective pharmacological options. They work by mimicking a hormone that reduces hunger and slows digestion. Clinical data shows they significantly increase the chance of losing weight compared to placebo, with tirzepatide and semaglutide showing the best results. These medications are FDA-approved for chronic weight management and should be used in combination with lifestyle changes.

Abdominal obesity (measured by waist circumference) is the most critical underlying risk factor for metabolic syndrome, serving as a strong proxy for insulin resistance and visceral fat accumulation.

Track your waist circumference, not just your weight. For men, a waist over 40 inches (102 cm) and for women over 35 inches (88 cm) indicates high risk. For Asian populations, lower thresholds (35 inches for men, 31.5 inches for women) apply. Reducing waist size is the most effective way to lower your risk of heart disease and diabetes.

For patients with type 2 diabetes and chronic kidney disease (CKD), SGLT2 inhibitors are recommended to reduce CKD progression, with GLP-1 receptor agonists as an alternative if SGLT2 inhibitors are contraindicated.

If you have diabetes and kidney disease, ask your doctor about SGLT2 inhibitors (like empagliflozin) or GLP-1 agonists (like liraglutide). These drugs have been proven to slow down kidney damage and reduce the risk of needing dialysis, offering benefits beyond just lowering blood sugar.

Excess visceral adipose tissue (VAT) is an independent risk factor for cardiovascular disease and mortality, regardless of overall body mass index (BMI).

Focus on waist circumference, not just weight. If your waist is large, your visceral fat is likely high, which drives heart disease risk even if your BMI is normal. Measure your waist and aim to reduce it through lifestyle changes.

Long-term use of FDA-approved obesity medications (orlistat, lorcaserin, phentermine/topiramate-ER) combined with lifestyle interventions produces statistically significant additional weight loss compared to placebo alone, with efficacy varying by drug class.

If you are struggling to maintain weight loss through diet and exercise alone, FDA-approved medications like Orlistat (120mg, 3x daily) can provide an additional 3-4% weight loss compared to lifestyle changes alone. This benefit comes with gastrointestinal side effects that are mitigated by keeping fat intake low. It is most effective when used as an adjunct to, not a replacement for, lifestyle interventions.

Phentermine plus topiramate-extended release (top dose) is the most effective FDA-approved obesity medication for long-term weight loss, producing approximately 9% weight loss relative to placebo at 1 year.

For patients with higher BMI and comorbidities who need significant weight loss, Phentermine/Topiramate (top dose) offers the highest efficacy (~10% loss). However, it requires a strict titration schedule and rigorous contraception for women of childbearing age due to birth defect risks. It is a high-efficacy, high-requirement option.

Postmenopausal weight loss of 10 kg or more, particularly when maintained, significantly decreases the risk of breast cancer in women who have never used postmenopausal hormones.

If you are postmenopausal and have never used hormone therapy, losing 10 kg or more and keeping it off can significantly lower your risk of breast cancer. This benefit is particularly strong for those who have never used postmenopausal hormones.

Once-weekly semaglutide 2.4 mg delivers significant weight loss (approx. 15-16% in non-diabetics, 9.6% in diabetics) and improves cardiovascular risk factors, and is FDA-approved for chronic weight management in adults with BMI ≥30 kg/m2 or ≥25 kg/m2 with comorbidities.

If you have type 2 diabetes and struggle with weight, once-weekly semaglutide 2.4 mg is a highly effective, FDA-approved option. It can lead to nearly 10% body weight loss when combined with lifestyle changes. While you may experience some gastrointestinal side effects, most people tolerate it well enough to stay on the medication, which is crucial for maintaining the weight loss and improving heart health markers.

Modest weight loss (5-10%) prevents type 2 diabetes in high-risk individuals, while greater weight loss (>10-15%) can induce remission of established type 2 diabetes, particularly when intervention occurs early in the disease course.

If you have prediabetes or early type 2 diabetes, losing just 5-10% of your body weight can significantly lower your risk of developing full-blown diabetes. If you already have diabetes, losing more weight (10-15%) can potentially put the disease into remission, especially if you act early. Focus on sustainable weight loss through diet, medication, or surgery as advised by your doctor, rather than just managing blood sugar with pills alone.

GLP-1 receptor agonists (GLP-1 RAs) promote significant, sustained weight loss in adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with comorbidities, primarily through central nervous system-mediated appetite suppression and reduced caloric intake, with efficacy superior to previously approved anti-obesity medications.

GLP-1 agonists like semaglutide and liraglutide are FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. They work by targeting hormonal pathways in the brain to reduce hunger and increase satiety, leading to significant, sustained weight loss that is roughly double that of older medications. Treatment is available in daily or weekly injectable forms, as well as oral tablets, and is intended for long-term use to maintain results without the 'Yo-Yo' effect common with short-term diets.

GLP-1 receptor agonists (specifically semaglutide 2.4 mg weekly and liraglutide 3.0 mg daily) produce significant weight loss in adults with obesity without diabetes, with semaglutide demonstrating superior efficacy compared to liraglutide.

For adults with obesity without diabetes, GLP-1 receptor agonists like semaglutide (2.4 mg weekly) and liraglutide (3.0 mg daily) are effective weight loss treatments. Semaglutide offers greater weight reduction than liraglutide. These drugs work by mimicking a hormone that increases satiety and slows digestion. Common side effects include gastrointestinal issues, which are often managed by starting with a lower dose and gradually increasing it.

Lowering blood pressure in Type 2 Diabetes patients reduces the risk of cerebrovascular accidents and congestive heart failure, with ACE inhibitors or ARBs recommended as first-line therapy.

Keep your blood pressure below 140/80 mmHg using ACE inhibitors or ARBs as your first medication. This is crucial for preventing strokes and heart failure in Type 2 Diabetes.

GLP-1 receptor agonists provide superior clinical outcomes compared to insulin in type 2 diabetes, offering better glycemic control, significant weight loss, and reduced hypoglycemia risk.

For type 2 diabetics struggling with oral meds, switching to a GLP-1 receptor agonist (like semaglutide or dulaglutide) is clinically superior to starting insulin. You will likely lose weight, have lower blood pressure, and avoid dangerous low-blood-sugar episodes, while achieving better or equal blood sugar control. These drugs are easier to use (up to once weekly) and do not require the complex titration of insulin.

GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and liraglutide produce significant, sustained weight reduction in adults with obesity by acting on the gut-brain axis to reduce appetite and food intake.

Semaglutide 2.4 mg injected once weekly, combined with lifestyle counseling, leads to an average 14.9% body weight loss in adults with obesity over 68 weeks. Side effects like nausea are common initially but typically subside; starting with a lower dose helps manage this.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces greater weight reduction than GLP-1 monotherapy in individuals with obesity without type 2 diabetes.

Tirzepatide 15 mg injected once weekly leads to an average 20.9% body weight loss in adults with obesity without diabetes over 72 weeks. This dual-action hormone therapy is more effective than GLP-1 monotherapy.

Tight blood-glucose control via traditional therapies does not significantly reduce macrovascular outcomes or heart failure risk in type 2 diabetes, whereas SGLT2 inhibitors and GLP-1 agonists significantly reduce cardiovascular mortality and heart failure hospitalization.

If you have Type 2 Diabetes and are at risk for heart issues, simply keeping your blood sugar numbers low with older medications may not protect your heart. Current guidelines recommend using specific newer medications (SGLT2 inhibitors or GLP-1 agonists) because they have proven to reduce the risk of heart failure and cardiovascular death, independent of their glucose-lowering effects. Discuss these specific classes with your doctor.

Second-generation anti-obesity medications (semaglutide 2.4 mg and tirzepatide) induce significantly greater weight loss (15-21%) compared to traditional lifestyle modification (5-10%) by pharmacologically enhancing satiation and reducing hunger, thereby decreasing the reliance on cognitive behavioral strategies for calorie restriction.

If you have obesity, second-generation medications like semaglutide or tirzepatide are significantly more effective than lifestyle changes alone, producing 15-21% weight loss compared to 5-10%. They work by reducing hunger and increasing fullness, which reduces the mental effort needed to restrict calories. While they require weekly injections and gradual dose titration to manage side effects, they represent a major advancement in obesity treatment.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered via once-weekly subcutaneous injections, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes and obesity compared to placebo, GLP-1 agonists, and basal insulin.

Tirzepatide is a once-weekly injection that activates two gut hormones (GIP and GLP-1) to help your pancreas release insulin when needed, slow down digestion, and reduce appetite. It is prescribed for type 2 diabetes and obesity. Clinical trials show it lowers blood sugar and body weight more effectively than many existing diabetes and weight-loss medications. Common side effects include nausea and diarrhea, which usually improve over time. It is taken alongside diet and exercise changes.